| Followers | 69 |
| Posts | 9464 |
| Boards Moderated | 0 |
| Alias Born | 04/05/2016 |
Tuesday, February 17, 2026 10:51:40 AM
Let’s separate your deranged emotion from reality for a second.
Preparing manufacturing capability before IDE approval is not “criminal.” It’s standard biotech protocol.
If you wait until after IDE clearance to:
• secure a production site
• validate equipment
• submit radiation handling licenses
• establish GMP protocols
—you delay first patient dosing by 6–12 months minimum.
Regulators expect readiness.
Manufacturing planning doesn’t = commercial production. It means being prepared if authorization is granted.
That’s called operational sequencing — not “cart before the horse.”
__________
Second:
No one is “putting Radiogel into human bodies without FDA approval.” IDE approval is required before U.S. trials begin. That is publicly acknowledged.
Preparing infrastructure while regulatory review proceeds is risk management — not fraud.
__________
Third:
Calling something “criminal per SEC standards” doesn’t make it so. If there were securities fraud:
• There would be an SEC investigation
• There would be enforcement action
• There would be trading suspension
None of that exists.
Throwing around legal accusations without evidence is reckless — not insightful.
__________
Finally:
If management truly believed the product had no path forward, they wouldn’t be investing in:
• facility readiness
• process scaling
• regulatory compliance buildout
Scams avoid capital expenditure.
They don’t prepare manufacturing pipelines.
You can disagree with timing.
You can dislike dilution history.
You can question strategy.
But calling standard biotech preparation “criminal” just exposes how little you understand how regulated medical manufacturing actually works.
When outrage replaces analysis, the argument’s already lost. And you’ve lost. Another swing and a miss!
Preparing manufacturing capability before IDE approval is not “criminal.” It’s standard biotech protocol.
If you wait until after IDE clearance to:
• secure a production site
• validate equipment
• submit radiation handling licenses
• establish GMP protocols
—you delay first patient dosing by 6–12 months minimum.
Regulators expect readiness.
Manufacturing planning doesn’t = commercial production. It means being prepared if authorization is granted.
That’s called operational sequencing — not “cart before the horse.”
__________
Second:
No one is “putting Radiogel into human bodies without FDA approval.” IDE approval is required before U.S. trials begin. That is publicly acknowledged.
Preparing infrastructure while regulatory review proceeds is risk management — not fraud.
__________
Third:
Calling something “criminal per SEC standards” doesn’t make it so. If there were securities fraud:
• There would be an SEC investigation
• There would be enforcement action
• There would be trading suspension
None of that exists.
Throwing around legal accusations without evidence is reckless — not insightful.
__________
Finally:
If management truly believed the product had no path forward, they wouldn’t be investing in:
• facility readiness
• process scaling
• regulatory compliance buildout
Scams avoid capital expenditure.
They don’t prepare manufacturing pipelines.
You can disagree with timing.
You can dislike dilution history.
You can question strategy.
But calling standard biotech preparation “criminal” just exposes how little you understand how regulated medical manufacturing actually works.
When outrage replaces analysis, the argument’s already lost. And you’ve lost. Another swing and a miss!
Recent RDGL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:44:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2025 09:14:29 PM
